3,5-Difluoropyridine-2,6-diamine | CAS:247069-27-8

We serve 3,5-Difluoropyridine-2,6-diamine CAS:247069-27-8 to global customers since 2007, Pls send inquiry to info@nbinno.com or visit www.nbinno.com our official website should you have any interests. This site is for information only.
3,5-Difluoropyridine-2,6-diamine

Chemical Name:3,5-Difluoropyridine-2,6-diamine
CAS.NO:247069-27-8
Synonyms:3,5-Difluoropyridine-2,6-diamine
3,5-Difluoro-pyridine-2,6-diamine
2,6-Diamino-3,5-difluoropyridine
 
Physical and Chemical Properties:
Density 1.5±0.1 g/cm3
Boiling Point 233.3±35.0 °C at 760 mmHg
Melting Point 160ºC
Molecular Formula C5H5F2N3
Molecular Weight 145.110
Flash Point 94.9±25.9 °C
 
Specification:
Appearance:White to off-white powder
Assay:≥98.0%
 
Packing:25 kg/drum, can also be packaged according to customer requirements
Storage:Store in a cool, ventilated place
Application:Intermediate of Delafloxacin.



Contact us for information like 3,5-Difluoropyridine-2,6-diamine chemical properties,Structure,melting point,boiling point,density,molecular formula,molecular weight,2,6-Diamino-3,5-difluoropyridine physical properties,toxicity information,customs codes,safety, risk, hazard and MSDS, CAS,cas number,3,5-Difluoropyridine-2,6-diamine Use and application,3,5-Difluoro-pyridine-2,6-diamine technical grade,usp/ep/jp grade.


Related News: The main API products include antihypertensive, psychotropic and anti-AIDS special APIs. Antihypertensive APIs are mainly pulic and sartan drugs, and they are the world’s major suppliers of pulic and sartan APIs.3,5-Dimethyl-4-hydroxybenzonitrile manufacturer Chinese President Xi Jinping vowed to tackle the spread of the virus, saying: “People’s lives and health should be given top priority and the spread of the outbreak should be resolutely curbed.”3,4-Dimethylaniline supplier Only when the drug substance is processed into a pharmaceutical preparation can it become a drug for clinical application.O-ethylhydroxylamine,hydrochloride vendor In April 2019, Glenmark had received approval from the Drugs Controller General of India (DCGI) for Remogliflozin Etabonate after successfully completing Phase-3 clinical trials.There are also new directives that relate to US citizens.